DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Avonex (Interferon Beta-1A) - Summary



AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein.

AVONEX® (Interferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. Safety and efficacy in patients with chronic progressive multiple sclerosis have not been established.

See all Avonex indications & dosage >>


Media Articles Related to Avonex (Interferon Beta-1A)

PLEGRIDY (Peginterferon Beta-1a) three-year data support long-term safety and efficacy in multiple sclerosis patients
Source: Multiple Sclerosis News From Medical News Today [2015.04.27]
Biogen has announced new data from the ATTAIN study which demonstrate the long-term safety and efficacy of PLEGRIDY® (peginterferon beta-1a) over three years in people with relapsing-remitting...

more news >>

Published Studies Related to Avonex (Interferon Beta-1A)

Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories. [2013]
The appearance of neutralizing antibodies (NAbs) has significant clinical and regulatory consequences for interferons in patients with multiple sclerosis (MS). In a double blind, randomized clinical trial, 84 patients with relapsing remitting MS were enrolled in a 24month study period... As similar results were obtained from CinnoVex or Avonex in our study, we suggest that both medications will have a similar immunogenetic profile.

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial. [2012]
USA) and CinnoVex (CinnaGen, Iran)... CONCLUSION: CinnoVex can be used as a safe and effective alternative to Avonex in

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. [2012]
combined with low-dose azathioprine and prednisone in multiple sclerosis... CONCLUSION: The tested combined therapeutic regimen does not improve long-term

Interferon beta for secondary progressive multiple sclerosis. [2012]
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. [2012]
This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers. Two randomized, blinded phase I studies were conducted: a single-dose study (n = 60) comparing subcutaneous or intramuscular PEG-IFN beta-1a (63, 125, or 188 µg) with intramuscular unmodified IFN beta-1a 30 µg and a multiple-dose study (n = 69) comparing subcutaneous PEG-IFN beta-1a dosed once every 2 or 4 weeks with placebo...

more studies >>

Clinical Trials Related to Avonex (Interferon Beta-1A)

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis [Completed]
The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.

Avonex (Interferon-Beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-Remitting MS [Active, not recruiting]
The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone. The study will also investigate whether combination therapy has any impact on the incidence of relapse and brain atrophy as measured by MRI.

Rebif New Formulation (RNF) Quality of Life Study [Active, not recruiting]
To evaluate the impact on Quality of Life, tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif.

Transition to Rebif New Formulation [Active, not recruiting]
To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44mcg three-times-weekly) to the new formulation of Rebif while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurance of flu-like symptoms.

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) [Recruiting]
The study is designed to determine the effect of weekly intramuscular (IM) administration of 30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and T2-weighted cranial magnetic resonance imaging (MRI) lesions in Chinese patients with clinically diagnosed (using revised McDonald criteria) relapsing multiple sclerosis (MS).

more trials >>

Reports of Suspected Avonex (Interferon Beta-1A) Side Effects

Influenza Like Illness (821)Multiple Sclerosis Relapse (734)Fall (726)Gait Disturbance (517)Fatigue (437)Pain (399)Headache (357)Memory Impairment (355)Injection Site Pain (335)Injection Site Haemorrhage (316)more >>

Page last updated: 2015-04-27

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015